How Big Will the SpaceX IPO Be?
Operated up to now as a private business, SpaceX will…
Sell
41
MESO Quote, Financials, Valuation and Earnings
Last price:
$17.02
Seasonality move
:
20.14%
Day range:
$16.60 - $17.37
52-week range:
$9.61 - $21.50
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
119.24x
P/B ratio:
4.33x
Volume:
136.8K
Avg. volume:
194.5K
1-year change:
-16.72%
Market cap:
$2.2B
Revenue:
$17.2M
EPS (TTM):
-$0.85
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
MESO
Mesoblast Ltd.
|
$23M | -- | -100% | -- | $35.00 |
|
ATHE
Alterity Therapeutics Ltd.
|
-- | -- | -- | -- | $12.00 |
|
IMMP
Immutep Ltd.
|
-- | -- | -- | -- | $9.50 |
|
IMRN
Immuron Ltd.
|
-- | -- | -- | -- | $3.47 |
|
KZIA
Kazia Therapeutics Ltd.
|
-- | -- | -- | -- | $18.94 |
|
PPCB
|
-- | -- | -- | -- | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
MESO
Mesoblast Ltd.
|
$16.99 | $35.00 | $2.2B | -- | $0.00 | 0% | 119.24x |
|
ATHE
Alterity Therapeutics Ltd.
|
$3.14 | $12.00 | $56.8M | -- | $0.00 | 0% | 3.58x |
|
IMMP
Immutep Ltd.
|
$2.70 | $9.50 | $393M | -- | $0.00 | 0% | -- |
|
IMRN
Immuron Ltd.
|
$0.81 | $3.47 | $4.7M | -- | $0.00 | 0% | 0.99x |
|
KZIA
Kazia Therapeutics Ltd.
|
$6.00 | $18.94 | $68M | -- | $0.00 | 0% | 270.88x |
|
PPCB
|
$11.98 | -- | $158.1K | -- | $0.00 | 0% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
MESO
Mesoblast Ltd.
|
-- | 2.607 | -- | -- |
|
ATHE
Alterity Therapeutics Ltd.
|
-- | 2.224 | -- | -- |
|
IMMP
Immutep Ltd.
|
-- | 0.527 | -- | -- |
|
IMRN
Immuron Ltd.
|
-- | 0.969 | -- | 5.77x |
|
KZIA
Kazia Therapeutics Ltd.
|
-6.76% | 4.448 | 5.57% | 0.07x |
|
PPCB
|
-- | 4.794 | -- | -- |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
MESO
Mesoblast Ltd.
|
-- | -- | -- | -- | -- | -- |
|
ATHE
Alterity Therapeutics Ltd.
|
-- | -- | -- | -- | -- | -- |
|
IMMP
Immutep Ltd.
|
-- | -- | -- | -- | -- | -- |
|
IMRN
Immuron Ltd.
|
-- | -- | -53.91% | -53.91% | -- | -- |
|
KZIA
Kazia Therapeutics Ltd.
|
-- | -- | -784.09% | -1083.16% | -- | -- |
|
PPCB
|
-- | -$290.8K | -- | -- | -- | -$235.5K |
Mesoblast Ltd. vs. Competitors
-
Which has Higher Returns MESO or ATHE?
Alterity Therapeutics Ltd. has a net margin of -- compared to Mesoblast Ltd.'s net margin of --. Mesoblast Ltd.'s return on equity of -- beat Alterity Therapeutics Ltd.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital MESOMesoblast Ltd.-- -- -- ATHEAlterity Therapeutics Ltd.-- -- -- -
What do Analysts Say About MESO or ATHE?
Mesoblast Ltd. has a consensus price target of $35.00, signalling upside risk potential of 106%. On the other hand Alterity Therapeutics Ltd. has an analysts' consensus of $12.00 which suggests that it could grow by 282.78%. Given that Alterity Therapeutics Ltd. has higher upside potential than Mesoblast Ltd., analysts believe Alterity Therapeutics Ltd. is more attractive than Mesoblast Ltd..
Company Buy Ratings Hold Ratings Sell Ratings MESOMesoblast Ltd.1 0 0 ATHEAlterity Therapeutics Ltd.0 0 0 -
Is MESO or ATHE More Risky?
Mesoblast Ltd. has a beta of 2.154, which suggesting that the stock is 115.386% more volatile than S&P 500. In comparison Alterity Therapeutics Ltd. has a beta of 0.114, suggesting its less volatile than the S&P 500 by 88.643%.
-
Which is a Better Dividend Stock MESO or ATHE?
Mesoblast Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Alterity Therapeutics Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Mesoblast Ltd. pays -- of its earnings as a dividend. Alterity Therapeutics Ltd. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios MESO or ATHE?
Mesoblast Ltd. quarterly revenues are --, which are smaller than Alterity Therapeutics Ltd. quarterly revenues of --. Mesoblast Ltd.'s net income of -- is lower than Alterity Therapeutics Ltd.'s net income of --. Notably, Mesoblast Ltd.'s price-to-earnings ratio is -- while Alterity Therapeutics Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Mesoblast Ltd. is 119.24x versus 3.58x for Alterity Therapeutics Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income MESOMesoblast Ltd.119.24x -- -- -- ATHEAlterity Therapeutics Ltd.3.58x -- -- --
-
Which has Higher Returns MESO or IMMP?
Immutep Ltd. has a net margin of -- compared to Mesoblast Ltd.'s net margin of --. Mesoblast Ltd.'s return on equity of -- beat Immutep Ltd.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital MESOMesoblast Ltd.-- -- -- IMMPImmutep Ltd.-- -- -- -
What do Analysts Say About MESO or IMMP?
Mesoblast Ltd. has a consensus price target of $35.00, signalling upside risk potential of 106%. On the other hand Immutep Ltd. has an analysts' consensus of $9.50 which suggests that it could grow by 251.85%. Given that Immutep Ltd. has higher upside potential than Mesoblast Ltd., analysts believe Immutep Ltd. is more attractive than Mesoblast Ltd..
Company Buy Ratings Hold Ratings Sell Ratings MESOMesoblast Ltd.1 0 0 IMMPImmutep Ltd.1 0 0 -
Is MESO or IMMP More Risky?
Mesoblast Ltd. has a beta of 2.154, which suggesting that the stock is 115.386% more volatile than S&P 500. In comparison Immutep Ltd. has a beta of 1.756, suggesting its more volatile than the S&P 500 by 75.579%.
-
Which is a Better Dividend Stock MESO or IMMP?
Mesoblast Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Immutep Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Mesoblast Ltd. pays -- of its earnings as a dividend. Immutep Ltd. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios MESO or IMMP?
Mesoblast Ltd. quarterly revenues are --, which are smaller than Immutep Ltd. quarterly revenues of --. Mesoblast Ltd.'s net income of -- is lower than Immutep Ltd.'s net income of --. Notably, Mesoblast Ltd.'s price-to-earnings ratio is -- while Immutep Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Mesoblast Ltd. is 119.24x versus -- for Immutep Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income MESOMesoblast Ltd.119.24x -- -- -- IMMPImmutep Ltd.-- -- -- --
-
Which has Higher Returns MESO or IMRN?
Immuron Ltd. has a net margin of -- compared to Mesoblast Ltd.'s net margin of --. Mesoblast Ltd.'s return on equity of -- beat Immuron Ltd.'s return on equity of -53.91%.
Company Gross Margin Earnings Per Share Invested Capital MESOMesoblast Ltd.-- -- -- IMRNImmuron Ltd.-- -- $6.4M -
What do Analysts Say About MESO or IMRN?
Mesoblast Ltd. has a consensus price target of $35.00, signalling upside risk potential of 106%. On the other hand Immuron Ltd. has an analysts' consensus of $3.47 which suggests that it could grow by 326.85%. Given that Immuron Ltd. has higher upside potential than Mesoblast Ltd., analysts believe Immuron Ltd. is more attractive than Mesoblast Ltd..
Company Buy Ratings Hold Ratings Sell Ratings MESOMesoblast Ltd.1 0 0 IMRNImmuron Ltd.0 0 0 -
Is MESO or IMRN More Risky?
Mesoblast Ltd. has a beta of 2.154, which suggesting that the stock is 115.386% more volatile than S&P 500. In comparison Immuron Ltd. has a beta of 0.824, suggesting its less volatile than the S&P 500 by 17.587%.
-
Which is a Better Dividend Stock MESO or IMRN?
Mesoblast Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Immuron Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Mesoblast Ltd. pays -- of its earnings as a dividend. Immuron Ltd. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios MESO or IMRN?
Mesoblast Ltd. quarterly revenues are --, which are smaller than Immuron Ltd. quarterly revenues of --. Mesoblast Ltd.'s net income of -- is lower than Immuron Ltd.'s net income of --. Notably, Mesoblast Ltd.'s price-to-earnings ratio is -- while Immuron Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Mesoblast Ltd. is 119.24x versus 0.99x for Immuron Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income MESOMesoblast Ltd.119.24x -- -- -- IMRNImmuron Ltd.0.99x -- -- --
-
Which has Higher Returns MESO or KZIA?
Kazia Therapeutics Ltd. has a net margin of -- compared to Mesoblast Ltd.'s net margin of --. Mesoblast Ltd.'s return on equity of -- beat Kazia Therapeutics Ltd.'s return on equity of -1083.16%.
Company Gross Margin Earnings Per Share Invested Capital MESOMesoblast Ltd.-- -- -- KZIAKazia Therapeutics Ltd.-- -- -$6.3M -
What do Analysts Say About MESO or KZIA?
Mesoblast Ltd. has a consensus price target of $35.00, signalling upside risk potential of 106%. On the other hand Kazia Therapeutics Ltd. has an analysts' consensus of $18.94 which suggests that it could grow by 215.86%. Given that Kazia Therapeutics Ltd. has higher upside potential than Mesoblast Ltd., analysts believe Kazia Therapeutics Ltd. is more attractive than Mesoblast Ltd..
Company Buy Ratings Hold Ratings Sell Ratings MESOMesoblast Ltd.1 0 0 KZIAKazia Therapeutics Ltd.1 0 0 -
Is MESO or KZIA More Risky?
Mesoblast Ltd. has a beta of 2.154, which suggesting that the stock is 115.386% more volatile than S&P 500. In comparison Kazia Therapeutics Ltd. has a beta of 1.775, suggesting its more volatile than the S&P 500 by 77.474%.
-
Which is a Better Dividend Stock MESO or KZIA?
Mesoblast Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Kazia Therapeutics Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Mesoblast Ltd. pays -- of its earnings as a dividend. Kazia Therapeutics Ltd. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios MESO or KZIA?
Mesoblast Ltd. quarterly revenues are --, which are smaller than Kazia Therapeutics Ltd. quarterly revenues of --. Mesoblast Ltd.'s net income of -- is lower than Kazia Therapeutics Ltd.'s net income of --. Notably, Mesoblast Ltd.'s price-to-earnings ratio is -- while Kazia Therapeutics Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Mesoblast Ltd. is 119.24x versus 270.88x for Kazia Therapeutics Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income MESOMesoblast Ltd.119.24x -- -- -- KZIAKazia Therapeutics Ltd.270.88x -- -- --
-
Which has Higher Returns MESO or PPCB?
has a net margin of -- compared to Mesoblast Ltd.'s net margin of --. Mesoblast Ltd.'s return on equity of -- beat 's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital MESOMesoblast Ltd.-- -- -- PPCB-- -$0.00 -- -
What do Analysts Say About MESO or PPCB?
Mesoblast Ltd. has a consensus price target of $35.00, signalling upside risk potential of 106%. On the other hand has an analysts' consensus of -- which suggests that it could fall by --. Given that Mesoblast Ltd. has higher upside potential than , analysts believe Mesoblast Ltd. is more attractive than .
Company Buy Ratings Hold Ratings Sell Ratings MESOMesoblast Ltd.1 0 0 PPCB0 0 0 -
Is MESO or PPCB More Risky?
Mesoblast Ltd. has a beta of 2.154, which suggesting that the stock is 115.386% more volatile than S&P 500. In comparison has a beta of 1.881, suggesting its more volatile than the S&P 500 by 88.104%.
-
Which is a Better Dividend Stock MESO or PPCB?
Mesoblast Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Mesoblast Ltd. pays -- of its earnings as a dividend. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios MESO or PPCB?
Mesoblast Ltd. quarterly revenues are --, which are smaller than quarterly revenues of --. Mesoblast Ltd.'s net income of -- is lower than 's net income of -$354.3K. Notably, Mesoblast Ltd.'s price-to-earnings ratio is -- while 's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Mesoblast Ltd. is 119.24x versus -- for . Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income MESOMesoblast Ltd.119.24x -- -- -- PPCB-- -- -- -$354.3K
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Where Will ISRG Stock Be in 5 Years?
Intuitive Surgical (NASDAQ:ISRG) is the innovative medical tech business behind…
Is Kratos Stock a Good Investment?
UAV and hypersonic system defense contractor Kratos (NASDAQ:KTOS) has swung…
Stock Ideas
Buy
52
Is NVDA Stock a Buy?
Market Cap: $4.2T
P/E Ratio: 59x
Buy
61
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 37x
Buy
53
Is GOOG Stock a Buy?
Market Cap: $4T
P/E Ratio: 41x
Alerts
Buy
61
SLAB alert for Feb 5
Silicon Laboratories, Inc. [SLAB] is up 48.74% over the past day.
Buy
73
ENPH alert for Feb 5
Enphase Energy, Inc. [ENPH] is up 38.57% over the past day.
Sell
25
MRCY alert for Feb 5
Mercury Systems, Inc. [MRCY] is down 22.24% over the past day.
